Science

Iridium catalyst activates chemotherapy drug directly at targeted cancer cells

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 03/11/2026, 18:25:28 UTC.

Briefings

A research team led by Dr. Thomas Ward at the University of Basel is developing a new chemotherapy approach using artificial metal compounds as catalysts. These compounds specifically bind to tumor cells to convert prodrugs into active ingredients directly at the cancer site, potentially reducing side effects on healthy tissue. The study was published in November 2026, but the specific mechanism of action and clinical efficacy remain to be fully tested.

Key points

• The research team led by Dr. Thomas Ward from the Department of Chemistry and the Swiss Nanoscience Institute (SNI) at the University of Basel is developing a chemotherapy approach using artificial metal compounds as catalysts.
• These catalysts specifically bind to tumor cells to convert prodrugs into active ingredients directly at the tumor site, potentially reducing side effects on healthy tissue.

Context

Conventional chemotherapy treatments often attack not only cancer cells but also healthy tissue, leading to severe side effects such as hair loss or nausea. This new approach aims to address these issues by targeting only cancer cells.

Limitations

The evidence is limited to a research study published in November 2026. Specific details on the exact mechanism of action, the specific metal compounds used, and the results of clinical trials are not provided in the source material.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 03/11/2026, 18:27:24 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeieimfdm3464fjdc3u77jpaht76lkmy22gnniayle7v7vtmb5i463m